Imugene (IMU) Price & Analysis

Compare

139 Followers

IMU Stock Chart & Stats

AU$0.33

>-AU$0.01(-2.22%)

At close: Jan 09 4:00 PM EST

AU$0.33

>-AU$0.01(-2.22%)

Day’s Range― - ―

52-Week RangeAU$0.18 - AU$1.39

Previous CloseN/A

Volume11.90M

Average Volume (3M)877.83K

Market Cap

AU$61.09M

Enterprise ValueAU$51.98M

Total Cash (Recent Filing)AU$14.14M

Total Debt (Recent Filing)AU$5.02M

Price to Earnings (P/E)―

Beta1.65

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding321,516,020

10 Day Avg. Volume850,615

30 Day Avg. Volume877,834

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.15

Price to Sales (P/S)21.99

P/FCF Ratio-1.07

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.18

Revenue Forecast (FY)AU$5.00M

Bulls Say, Bears Say

Bulls Say

Conservative Capital StructureLow leverage (debt/equity 0.24) provides durable financial flexibility for a clinical-stage biotech. Limited debt reduces fixed obligations, preserving ability to fund R&D via equity or partnerships and lowering bankruptcy risk during multi-year development cycles.

Diverse Immuno-oncology PipelineMultiple programs across oncolytic viruses and vaccine candidates spread technical and regulatory risk. A diversified pipeline increases chances of a successful asset, supports multiple partnering/licensing pathways, and aligns with long-term immuno-oncology growth trends.

Clear Partnership/licensing Monetization PathReliance on partnerships and licensing is a durable commercialization model for clinical-stage biotechs. Structured deals can fund trials, transfer commercialization risk, and provide milestone/royalty upside, reducing need to build costly in-house commercial capability.

Bears Say

Severe Revenue DeclineAn extreme revenue contraction indicates the company lacks a stable commercial revenue base. This structural shortfall increases dependency on external financing, heightens dilution risk, and constrains the firm's ability to self-fund ongoing clinical programs over multiple years.

Deeply Negative Returns And ProfitabilityVery negative ROE and margins show the business is destroying equity and not converting investment into profits. Persistent unprofitability undermines long-term shareholder value, may weaken negotiating leverage with partners, and raises the bar for achieving sustainable economics.

Weak Operating Cash GenerationNegative operating cash flow is a durable red flag: core operations consume cash rather than generate it. Until clinical successes or partner funding arrive, the company will depend on capital markets, increasing execution risk and potential funding-related delays for trials.

Imugene News

Imugene Issues Additional Unquoted Options Under Capital Management Plan

Imugene ( ($AU:IMU) ) has shared an update. Imugene Limited has notified the market of the issue of...

10h ago

Imugene Seeks ASX Quotation for Additional Ordinary Shares

Imugene ( ($AU:IMU) ) just unveiled an announcement. Imugene Limited has applied to the ASX for quotation of...

10h ago

Imugene outlines non-underwritten capital raising with strict offer restrictions

Imugene ( ($AU:IMU) ) just unveiled an update. Imugene Limited has released a capital raising presentation outlining plans...

2d ago

Imugene Launches Securities Purchase Plan Offering Shares and New Quoted Options

The latest announcement is out from Imugene ( ($AU:IMU) ). Imugene Limited has announced a new securities purchase...

2d ago

Imugene plans major equity and options issue to support growth

Imugene ( ($AU:IMU) ) just unveiled an update. Imugene Limited has outlined plans for a new capital raising...

2d ago

Imugene Secures $12m Placement in $20m Capital Raise to Fund Azer-cel Trial

Imugene ( ($AU:IMU) ) has shared an announcement. Imugene has launched a capital raising of approximately $20 million...

2d ago

Imugene posts high response rates for azer-cel in early CAR T-naïve lymphoma trial

The latest update is out from Imugene ( ($AU:IMU) ). Imugene reported strong early efficacy data from the...

3d ago

Imugene Seeks Trading Halt Ahead of Capital Raising Announcement

Imugene ( ($AU:IMU) ) has issued an update. Imugene has requested an immediate trading halt in its securities...

3d ago

Imugene’s VAXINIA Trial Termination: What the Latest Clinical Update Means for IUGNF Investors

Imugene Ltd ($IUGNF) announced an update on their ongoing clinical study. The phase I MAST study tests Imugene...

6d ago

IUGNF

Imugene’s OASIS Trial Termination: What It Means for IUGNF Investors

Imugene Ltd ($IUGNF) announced an update on their ongoing clinical study. The OASIS study, officially titled “A Phase...

6d ago

IUGNF

IMU FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest share price was AU$0.18 and its highest was AU$1.39 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is AU$61.09M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Aug 28, 2026 which is in 169 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Imugene have?

Imugene has 321,516,020 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in AU:IMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Underperform

Fundamentals

Return on Equity

-134.65%

Trailing 12-Months

Asset Growth

-39.73%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.